Compare TCRT & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | CELZ |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.8M |
| IPO Year | 2025 | 2008 |
| Metric | TCRT | CELZ |
|---|---|---|
| Price | $2.15 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.1K | ★ 62.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.66 | ★ 32.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,900,000.00 | $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $1.50 |
| 52 Week High | $5.48 | $6.25 |
| Indicator | TCRT | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 38.77 |
| Support Level | $1.92 | $1.74 |
| Resistance Level | $2.37 | $1.99 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 25.49 | 10.53 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.